# The U.S Bacterial Conjunctivitis Drugs Market To Steadily Get Innovative
Author:  Pal Sinha, Barnali 
Author URL: https://financedigest.com/author/pal-sinha-barnali
Published: 2021-11-26
Category: Research Reports
Category URL: https://financedigest.com/category/research-reports
Meta Title: U.S. Bacterial Conjunctivitis Drugs Market Report 2024
Meta Description: Discover insights into the bacterial conjunctivitis drugs market in the U.S. and the projected growth of fluoroquinolones as the largest segment by 2024.
URL: https://financedigest.com/the-u-s-bacterial-conjunctivitis-drugs-market-to-steadily-get-innovativehtml

![undefined](https://prod.superblogcdn.com/site_cuid_cm5qst7v3003gwirgwqtxn8i8/images/research-report-2-1736836864071-compressed.jpg)

According to a new market report published by Persistence Market Research “ **The U.S Market Study on Bacterial Conjunctivitis Drugs: fluoroquinolones to be the Largest Segment by 2024**” the bacterial conjunctivitis drugs market in the U.S. was valued at **USD 473.3 million** in 2013 and is [estimated](https://www.financedigest.com/spotifys-monthly-active-users-top-500-million-beat-estimate.html "Spotify’s monthly active users top 500 million, beat estimate") to reach a market worth of **USD 439.8 million** in 2024, at a **CAGR of 2.7%** from 2012 to 2018 and (-3.73%) from 2018 to 2024.

Conjunctivitis is an inflammation of the conjunctiva – the clear membrane that covers the outermost layer of an eye and the inner surface of eyelids. Conjunctivitis is segmented into three major categories: infective (viral and bacterial), allergic, and irritant (chemical). Bacterial conjunctivitis is one of the most commonly observed eye problems across all age groups, generally caused by bacteria such as Staphylococcus aureus, Moraxella lacunata, Haemophilus influenza, and others (e.g. Chlamydia trachomatis, Proteus mirabilis, etc.).

**Get Sample Copy of this Report@** [**https://www.persistencemarketresearch.com/samples/5192**](https://www.persistencemarketresearch.com/samples/5192)

**Company Profiles:**

- Actavis plc.
- Akorn, Inc.
- Bayer AG.
- F. Hoffmann-La Roche, Ltd.
- Merck & Co., Inc.
- Novartis AG.
- Perrigo Company plc, Pfizer, Inc.
- Santen Pharmaceutical Co., Ltd.
- Valeant Pharmaceuticals International, Inc.

**Request for Methodology@** [**https://www.persistencemarketresearch.com/methodology/5192**](https://www.persistencemarketresearch.com/methodology/5192)

As reported by Healio (specialty medical news and journal publisher), approximately 5 million acute bacterial conjunctivitis cases are reported in the U.S. each year. Thus, high prevalence of bacterial conjunctivitis in the country demands effective medications, thereby [driving the growth of the bacterial conjunctivitis drugs market](https://www.financedigest.com/increasing-incidences-of-spinal-fractures-to-drive-the-osteoporosis-drugs-market.html "Increasing incidences of spinal fractures to drive the Osteoporosis Drugs Market") in the U.S.However, [despite the increasing](https://www.financedigest.com/global-medical-costs-expected-to-increase-in-2017-despite-lower-rates-of-inflation.html "Global Medical Costs Expected to Increase in 2017 Despite Lower Rates of Inflation") incidence of bacterial conjunctivitis, the overall bacterial conjunctivitis market in the U.S. is likely to witness negative growth due to the patent expirations of major blockbuster drugs such as Vigamox, Moxeza, Zymaxid, and Besivance in the [next few years](https://www.financedigest.com/start-up-etioca-eyes-nasdaq-listing-next-year-as-it-unveils-electric-taxi.html "Start-up Etioca eyes Nasdaq listing next year as it unveils electric taxi").

[Rise in ophthalmic bacterial infections is increasing the demand](https://www.financedigest.com/uk-home-asking-prices-rise-tax-cuts-to-spur-demand-rightmove.html "UK home asking prices rise, tax cuts to spur demand: Rightmove") for antibacterial drugs in the U.S. [According to a clinical study](https://www.financedigest.com/us-homeowners-premium-set-to-surpass-90bn-for-the-first-time-according-to-annual-aon-study.html "US homeowners premium set to surpass bn for the first time, according to annual Aon study") conducted by the scientists Amir A. Azari and Neal P. Barney, published in the Journal of the American Medical Association (JAMA) in 2013, bacterial conjunctivitis accounts for over 50% of the conjunctivitis cases in the U.S. It also quoted that the incidence of bacterial conjunctivitis was estimated to be 135 in 10,000 in a single study.These statistics indicate that the U.S. is witnessing high incidence of bacterial conjunctivitis, hence [leading to increased demand for bacterial conjunctivitis drugs](https://www.financedigest.com/generic-oncology-drugs-market-2021-global-leading-companies-analysis-revenue-trends-and-forecasts-2027.html "Generic Oncology Drugs Market 2021 Global Leading Companies Analysis, Revenue, Trends and Forecasts 2027") in the country.

Fluoroquinolones, aminoglycosides, macrolides and other antibacterials such as bacitracin, doxycycline, and ceftriaxone collectively form the bacterial conjunctivitis market; among which fluoroquinolones dominate the bacterial conjunctivitis [drugs market](https://www.financedigest.com/the-peptic-ulcer-drugs-market-to-proliferate-with-digitized-upswing.html "The Peptic Ulcer Drugs Market to proliferate with digitized upswing") in the U.S. with a share of more than 70% in 2013. Fluoroquinolones are more widely prescribed as compared to other antibiotic drug classes for the treatment of bacterial conjunctivitis across the U.S. due to their higher efficacy against antibiotic-resistant bacterial strains and broad spectrum activity.

However, the segment is expected to [witness a significant decline in sales in the near future -from a CAGR](https://www.financedigest.com/pcb-design-software-market-to-witness-an-attractive-cagr-of-15.html "PCB Design Software Market to witness an attractive CAGR of 15%") of 4.9% from 2012 to 2018 to a CAGR of (-8.1%) from 2018 to 2024. Burgeoning influx of generic antibacterials as well as upcoming patent expiries of leading branded formulations such as Vigamox, Zymaxid, Moxeza, and Besivance are a few major [factors that would adversely affect](https://www.financedigest.com/home-equity-release-how-to-get-the-best-valuation-and-what-factors-can-affect-it.html "Home Equity Release: How to Get the Best Valuation and What Factors Can Affect it?") the growth of the segment.

With the loss of patent exclusivity, generics would offer physicians a broad range of affordable medications to prescribe, thereby significantly reducing the overall [size of the bacterial conjunctivitis drugs market](https://www.financedigest.com/planting-equipment-market-size-consumption-comparison-by-application-2021-2029.html "Planting Equipment Market Size Consumption Comparison By Application (2021-2029)") in the U.S. Hence, the [future market growth](https://www.financedigest.com/portugals-q3-growth-accelerates-with-consumption-but-future-not-shining.html "Portugal’s Q3 growth accelerates with consumption but future not shining") would be contingent on commercialization of novel drugs for new indications.

However, it has been observed that although the incidence rate of bacterial conjunctivitis is moderate in the U.S., the risk of morbidity is less, [due to which the novel product](https://www.financedigest.com/apple-likely-to-cut-iphone-13-production-due-to-chip-crunch-bloomberg-news.html "Apple likely to cut iPhone 13 production due to chip crunch -Bloomberg News") pipeline for bacterial conjunctivitis is weak/dry. At present, only a few novel compounds are under investigation in both preclinical and clinical settings for the treatment of bacterial conjunctivitis.

**Access Full Report@** [**https://www.persistencemarketresearch.com/checkout/5192**](https://www.persistencemarketresearch.com/checkout/5192)

**The U.S. bacterial conjunctivitis [drugs market](https://www.financedigest.com/the-drug-repurposing-market-to-virtually-grow-beyond-geographies.html "The Drug Repurposing Market to virtually grow beyond geographies") is segmented as follows:**

**U.S. Bacterial Conjunctivitis [Drugs Market](https://www.financedigest.com/the-antiobesity-drugs-market-to-tilt-towards-digitization.html "The Antiobesity Drugs Market to tilt towards digitization"), by Drug Class**

- Fluoroquinolones
  - Ciprofloxacin
  - Ofloxacin
  - Levofloxacin
  - Moxifloxacin
  - Gatifloxacin
  - Besifloxacin

- Aminoglycosides
  - Tobramycin
  - Gentamycin

- Macrolides
  - Erythromycin
  - Azithromycin

- Others

**U.S. Bacterial Conjunctivitis [Drugs Market](https://www.financedigest.com/the-celiac-drugs-market-to-grow-at-an-exponential-substantiation.html "The Celiac Drugs Market to grow at an exponential substantiation"), Pipeline Assessment**

- Vancomycin Ophthalmic Ointment
- [Early Stage](https://www.financedigest.com/valuing-your-early-stage-startup.html "Valuing your Early Stage Startup") (Phase I and Phase II trials) – Tabular Representation

**[Related](https://www.financedigest.com/aonponemon-report-almost-four-times-more-budget-is-being-spent-on-property-related-risks-vs-cyber-risk.html "Aon/Ponemon report: Almost four times more budget is being spent on property related risks vs. cyber risk") Reports:**

[**Sarcopenia Treatment Market**](https://www.persistencemarketresearch.com/market-research/sarcopenia-treatment-market.asp)

[**Rheumatoid Arthritis Treatment Market**](https://www.persistencemarketresearch.com/market-research/rheumatoid-arthritis-treatment-market.asp)

**About Us:** [**Persistence Market Research**](https://www.persistencemarketresearch.com/about-us.asp)

**Contact Us:**

**[Persistence Market](https://www.financedigest.com/the-pharmaceutical-packaging-market-to-stay-innovatively-persistent.html "The Pharmaceutical Packaging Market to stay innovatively persistent") Research**

Address – 305 Broadway, 7th Floor, New [York City](https://www.financedigest.com/dr-letao-qin-joins-rimon-as-partner-in-its-research-triangle-park-and-new-york-city-offices.html "Dr.Letao Qin, joins Rimon as Partner in its Research Triangle Park and New York City Offices"),

NY 10007 United States

U.S. Ph. – +1-646-568-7751

USA-Canada Toll-free – +1 800-961-0353

**Japan Office:** 1-2-1 Kinshi Arca [Central Building](https://www.financedigest.com/bosch-to-build-215-million-plant-in-central-mexico.html "Bosch to build 5 million plant in central Mexico")

14/F Tokyo, 130-0013, Japan

Call 1-888-863-3700

**Sales** – sales@persistencemarketresearch.com

**Website** – [https://www.persistencemarketresearch.com](https://www.persistencemarketresearch.com/)


---
This blog is powered by Superblog. Visit https://superblog.ai to know more.
---